Protalix BioTherapeutics, Inc. reported its financial results for the fiscal quarter ended September 30, 2026, and provided an update on its clinical and commercial operations. The company announced that total revenues increased by $32.0 million year-to-date to $75.6 million, compared to $43.6 million for the same period in 2025.
For the third quarter of 2026, net income was $4.0 million, or $0.05 per share, compared to $2.4 million, or $0.03 per share, in the prior year. For the nine months ended September 30, 2026, net income was $26.1 million, or $0.33 per share basic and $0.31 per share diluted, compared to a net loss of $1.1 million in the prior year.
As of September 30, 2026, the company held $48.5 million in cash, cash equivalents, and short-term bank deposits. Protalix has no outstanding debt or warrants. The company reaffirmed its 2026 revenue guidance, expecting total revenues of approximately $78.0 million to $83.0 million, including a $25.0 million milestone payment received from Chiesi in the first quarter of 2026.
On the business front, Protalix announced that its partner, Chiesi Global Rare Diseases, received marketing authorization in Brazil for Elfabrio for both every-two-weeks and every-four-weeks dosing regimens. The company also provided an update on its PRX-115 Phase 2 RELEASE study, a double-blind, placebo-controlled trial for uncontrolled gout. Patient enrollment is continuing, and top-line results are anticipated in the second half of 2027. Additionally, the company presented new individual patient data at the American College of Rheumatology (ACR) Convergence 2026, reinforcing findings that higher single doses of PRX-115 lowered mean plasma uric acid for longer durations.
